

The Ordinary-Niacinamide 10% + Zinc 1%
₨ 3,700 Original price was: ₨ 3,700.₨ 3,199Current price is: ₨ 3,199.
The Ordinary Niacinamide 10% + Zinc 1% is a high-strength serum designed to reduce the appearance of blemishes, uneven skin tone, and excess oil production. With 10% niacinamide and 1% zinc, it helps to balance skin while improving the overall complexion.
In stock
Description
The Ordinary Niacinamide 10% + Zinc 1% is a potent formula designed to target multiple skin concerns, especially for those with oily, acne-prone, or blemish-prone skin. Niacinamide (vitamin B3) at a 10% concentration helps to reduce the appearance of enlarged pores, improve uneven skin tone, and regulate sebum production, while zinc at 1% works to reduce inflammation and support the skin’s natural healing processes. This lightweight serum not only helps to prevent breakouts but also strengthens the skin’s barrier, improving overall skin texture and clarity. With consistent use, this formula balances oily areas and helps to refine the appearance of pores, leaving the skin looking smoother, clearer, and more even-toned. Ideal for anyone dealing with acne, oiliness, or skin congestion.
Additional information
Brand |
The Ordinary |
---|
Related products
AXIS-Y-Calamine Pore Control Capsule Serum 50ml
In stock
Beauty of Joseon-Glow Deep Serum : Rice +Alpha Arbutin 30ml
In stock
Beauty of Joseon-Glow Serum : Propolis+Niacinamide 30ml
In stock
Beauty of Joseon-Revive Serum : Ginseng+Snail Mucin 30ml
In stock
The Ordinary Retinol 1% In Squalane 30ml
In stock
The Ordinary-Caffeine Solution 5% + EGCG
In stock
The Ordinary Caffeine Solution 5% + EGCG is a lightweight eye serum designed to reduce the appearance of puffiness and dark circles. Infused with caffeine and EGCG (Epigallocatechin Gallatyl Glucoside), it helps to refresh and energize the skin around the eyes, leaving it looking more awake and revitalized
The Ordinary-Salicylic Acid 2% Masque.
In stock
The Ordinary-Vitamin C Suspension 23% + HA Spheres 2%
In stock
Reviews
There are no reviews yet.